• Mission
  • Leadership
  • Approach
  • Focus
    • Research
    • Pipeline
  • FAQ
  • Careers
  • Connect

Mission

Who we are

The Bill & Melinda Gates Medical Research Institute is a non-profit organization dedicated to the development and effective use of novel biomedical interventions addressing substantial global health concerns, for which investment incentives are limited.

The institute works through collaborating partners and organizations, coordinating and driving the full spectrum of biopharmaceutical development activities, including pre-clinical development, full clinical development (from phase 1 through phase 3) and global regulatory interactions.

what we do

The institute focuses on programs aimed at reducing the burden of TB, malaria, diarrheal diseases, and maternal, newborn, and child illnesses.

As an affiliate of the Bill & Melinda Gates Foundation, the institute’s programs are focused on disease and health areas of primary focus at the foundation. The interventions under study and development are derived from sources both within and external to the foundation.

Leadership

Our Explorers

We bring interdisciplinary experience to the pursuit of saving lives.

Emilio A. Emini, Ph.D., FCPP, FAAM

Chief Executive Officer

As CEO of the Bill & Melinda Gates Medical Research Institute, Emilio A. Emini, Ph.D. leads the Institute’s research and development of novel products and interventions for diseases disproportionately impacting the world’s most vulnerable populations.

Before joining the Gates MRI, Emilio served as director of the HIV and Tuberculosis program at the Bill & Melinda Gates Foundation, where he led the foundation’s efforts focused on accelerating the reduction in the incidence of HIV and TB in high-burden geographies, with the goal of achieving sustained epidemic control. Over the course of his previous 30-year career in the biopharmaceutical industry, Emilio led teams involved in the research and development of novel anti-infectives and vaccines. From 1983 to 2004, he led research at the Merck Research Laboratories involved in the development of one of the first highly active antiretroviral therapies for HIV and, as senior vice president of vaccine research, the successful development of a number of vaccines including vaccines for human papillomavirus and rotavirus.

He later served as senior vice president of vaccine development at the International AIDS Vaccine Initiative. From 2005 to 2015, he was senior vice president of vaccine R&D at Pfizer Inc., leading the development of Prevnar 13® for prevention of pneumococcal disease.

Emilio was awarded the Distinguished Alumnus Award from the Weill Cornell University Graduate School of Medical Sciences in 2006. He is a former trustee of the National Foundation for Infectious Diseases and a former member of the National Preparedness & Response Science Board, an advisory committee to the U.S. Secretary of Health and Human Services. He is an elected fellow of the American Academy of Microbiology, International Society for Vaccines, and The College of Physicians of Philadelphia. He received his Ph.D. in Microbiology, Genetics, and Biochemistry from the Weill Cornell University Graduate School of Medical Sciences.

Michael Dunne, M.D., FIDSA

Chief Medical Officer, Head of Development

As chief medical officer and head of development at the Bill & Melinda Gates Medical Research Institute, Michael W. Dunne, M.D., oversees clinical trials in therapeutic areas aligned with the mission of the Gates Foundation.

Over the course of his career, Michael has played an integral role in global and local anti-infective drug development. Prior to joining the Institute, Michael was the founder and chief scientific officer at Iterum Therapeutics, where he led the development of the antibiotic sulopenem. From 2014 to 2015, he was vice president of research and development at Actavis. Michael earlier served as founder and chief medical officer at Durata Therapeutics beginning in 2009, where he was responsible for the development and successful global registration of dalbavancin. Prior to joining Durata, Michael worked at Pfizer for 17 years, leading the development and registration of several antibacterial, antifungal, antiviral, and HIV therapeutics. Michael was a member of the Scientific Advisory Committee for the Global Alliance for TB Drug Development and a member of the Expert Scientific Advisory Committee for the Medicines for Malaria Venture.

Michael currently serves on the Board of Directors at Iterum Therapeutics and is on the Editorial Review Board of the journal Clinical Infectious Diseases. He is a member of the Scientific Advisory Board for The Singapore-MIT Alliance for Research and Technology and a fellow of the Infectious Diseases Society of America. He earned his M.D. from the State University of New York Health Science Center at Brooklyn and completed his residency in internal medicine and fellowship training in pulmonary medicine and infectious diseases at Yale University.

Manfred Lauchart, Ph.D

Head of Program & Portfolio Management

As head of program & portfolio management at the Bill & Melinda Gates Medical Research Institute, Manfred Lauchart, Ph.D., ensures the delivery of highly-needed medicinal products by driving strategic planning and execution of development programs.

Manfred has extensive product development experience in Fortune 500 Life Science companies, business units, and small biotech start-ups, leading international and cross-functional teams to develop, launch, and sustain life-saving biopharmaceutical and medical device products. Prior to joining the Institute, Manfred served as vice president and head of program management organization at Intarcia Therapeutics, where he drove planning and execution of the pipeline portfolio from 2017 to 2020. Prior to Intarcia, he served as an independent consultant providing and implementing program management solutions for life science companies. As senior director of R&D, head of business operations for global clinical development, and chief of staff at Baxalta, he optimized business processes and secured compliance with existing regulatory requests as well as new R&D standards. From 2003 to 2015, Manfred served as senior director program management office R&D at Baxter Bioscience and Baxter Medical Products divisions, leading international teams in the US, EU, and Asia advancing vaccine, pharmaceutical, and medical device development programs through all stages of product development to licensure and product launch.

Manfred earned his Master of Science in Microbiology and Immunology and his Ph.D. from the University of Vienna, Austria. He later earned a Master of Management degree from Malik Management Centre in St. Gallen, Switzerland.

Ken Miller, J.D.

Lead Counsel

As lead counsel at the Bill & Melinda Gates Medical Research Institute, Ken A. Miller, J.D., delivers efficient and reliable legal guidance, manages legal risk, and supports the development of solutions that accelerate impact.

Ken is a business, technology, and global health attorney with more than 20 years of experience working with highly innovative companies and nonprofits, focusing on the life sciences, software, and semiconductor industries, to help them achieve their business and charitable objectives. Prior to joining the Gates MRI in 2021, Ken supported the Global Health Division of the Bill & Melinda Gates Foundation for five years as associate general counsel, where he helped to structure and negotiate some of the Foundation’s most substantial investments and collaborations in TB, HIV, and vaccine development. From 2005 to 2015 he was a partner of the Technology Transactions and Privacy Group at Perkins Coie LLP. In this role, Ken advised technology companies and nonprofits in complex, high-value IP and commercial transactions covering the entire product life cycle, from discovery through manufacturing and commercialization for small molecules, biologics, and devices.

Ken is a member of the Licensing Executives Society and a member of the Board of Trustees and Executive Committee at Epiphany School. He earned his J.D. from Seattle University School of Law.

Taryn Rogalski-Salter, Ph.D.

Head of Global Regulatory Strategy & Operations

As head of global regulatory strategy and operations at the Bill & Melinda Gates Medical Research Institute, Taryn Rogalski-Salter, Ph.D., and her team develops and implements innovative global regulatory strategies that support accelerated product development, playing a critical role in helping to advance drug and vaccine candidates toward licensure globally.

Throughout her 25-year career in manufacturing, analytical development, global regulatory policy, and regulatory affairs, Taryn has been directly involved in the global licensure of nearly a dozen new vaccines. Prior to joining the Institute, Taryn was vice president and head of global regulatory affairs at Takeda Vaccines, where she was responsible for all regulatory aspects including norovirus, dengue, sIPV, and Zika vaccine candidates. From 2008 to 2012, Taryn served as vice president and global head of vaccine regulatory affairs at Novartis Vaccines & Diagnostics, achieving global licensure of vaccines for influenza and meningitis. As vice president of global regulatory Chemistry, Manufacturing, and Controls (CMC) at Novartis Pharmaceuticals Corporation from 2007 to 2008, she was responsible for all CMC aspects concerning developmental and marketed products. Prior to her work at Novartis, she held various leadership roles in regulatory affairs and global regulatory policy at Merck and GlaxoSmithKline from 1994 to 2007.

Taryn has extensive experience in global regulatory policy and has occupied elected and volunteer positions in pharmaceutical trade organizations including PhRMA, BIO, and IFPMA. Taryn received her Ph.D. from Dartmouth College and conducted her thesis research on applied genetic and metabolic engineering at Dartmouth's Thayer School.

Jared Silverman, Ph.D.

Head of Translational Discovery

As head of translational discovery at the Bill & Melinda Gates Medical Research Institute, Jared A. Silverman, Ph.D., drives products from idea to commercialization in disease areas that disproportionately impact vulnerable populations worldwide.

Jared has more than 20 years of experience in drug discovery spanning multiple therapeutic areas, with a primary focus on antibiotics for the treatment of serious hospital infections. Prior to joining the Institute, Jared was senior vice president of research at Kaleido Biosciences, where he was responsible for building a drug discovery platform to identify novel modulators of the microbiome for the prevention and treatment of disease. From 1997 to 2015, he was a member of the research team at Cubist Pharmaceuticals (including five years as vice president of biology) where he contributed to the discovery of three novel antibiotics that entered clinical development.

Jared has served on the Board of Directors of Auspherix and Procarta Biosciences, and is an editor for Antimicrobial Agents and Chemotherapy. He earned his Ph.D. in Microbiology and Molecular Genetics from Harvard University.

Claire Wagner, M.D., MBA

Head of Corporate Strategy

As head of corporate strategy at the Bill & Melinda Gates Medical Research Institute, Claire M. Wagner, M.D., M.B.A., drives forward the Institute’s mission and vision, advising the CEO on enterprise-level strategy across a range of vantage points. Prior to her role as head of corporate strategy, Claire served as chief of staff.

Claire has led multi-country studies and consulted for industry and non-profit entities focused on enhancing global access to oncology products and services in low- and middle-income countries. Prior to joining the Institute, Claire worked in Mali and Tanzania between 2007 and 2009 and later served in Rwanda from 2010 to 2013 on a research team advancing large public sector health initiatives.

After returning to the United States, Claire coordinated a global effort led by the Dana-Farber Cancer Institute and the Union for International Cancer Control, resulting in the 16-drug expansion of the World Health Organization's Model List of Essential Medicines for cancer. As a research fellow of the Harvard-Dubai Center for Global Health Delivery in 2018-19, Claire was principal investigator on a study evaluating access to cancer diagnostics in the East African Community.

Claire is the recipient of The Commonwealth Institute’s 2021 Extraordinary Women Advancing Healthcare Award. She is an associate scientist in medicine in the Division of Global Health Equity at the Brigham and Women’s Hospital and is a co-author of more than 40 scientific publications in peer-reviewed journals, including Nature, The Lancet, and The New England Journal of Medicine. Claire earned her M.D. from Harvard Medical School and her M.B.A. from Harvard Business School, where she was the Commencement Class Day Speaker.

Debra Weiss, RN, MSN

Chief Operating Officer

As chief operating officer at the Bill & Melinda Gates Medical Research Institute, Debra Weiss, RN, MSN, provides strategic and operational support to achieve business objectives in compliance with Institute and industry standards for data integrity, safety, and quality. She has overseen operations since the Institute was founded in January 2018. Prior to her role as COO, Debra served as the Institute’s head of quality assurance & enterprise operations.

Debra’s diverse background ranges from conducting clinical trials in an academic environment to working in large and small pharmaceutical companies, where she traveled globally auditing clinical trial activities and leading global QA organizations. Prior to joining the Institute, Debra served as president of Compliance Driven Performance LLC, where she provided quality assurance and compliance consulting to facilitate companies in building and sustaining their Quality Management System. From 2004 to 2015, she served as group vice president of R&D quality assurance at Shire Pharmaceuticals and was named Shire’s Healthcare Business Women Association Rising Star in 2008. Before Shire, Debra was manager of worldwide clinical quality assurance at Merck & Co., Inc., where she led a team of quality assurance auditors and participated in a pilot program with the FDA on the use of electronic diaries. A registered nurse by training, Debra held various roles at the Hospital of the University of Pennsylvania and Hahnemann University Hospital from 1986 to 1996.

Debra is an adjunct professor at Temple University teaching a graduate course in GCPs. She earned her MSN from the University of Pennsylvania and BSN from Hahnemann University (Drexel).

Emilio Emini, Ph.D., FCPP, FAAM
Michael Dunne, M.D., FIDSA
Manfred Lauchart, Ph.D
Ken Miller, J.D.
Taryn Rogalski-Salter, Ph.D.
Jared Silverman, Ph.D.
Claire Wagner, M.D., MBA
Debra Weiss, RN, MSN

Chief Executive Officer

Emilio A. Emini, Ph.D., FCPP, FAAM

As CEO of the Bill & Melinda Gates Medical Research Institute, Emilio A. Emini, Ph.D. leads the Institute’s research and development of novel products and interventions for diseases disproportionately impacting the world’s most vulnerable populations.

Before joining the Gates MRI, Emilio served as director of the HIV and Tuberculosis program at the Bill & Melinda Gates Foundation, where he led the foundation’s efforts focused on accelerating the reduction in the incidence of HIV and TB in high-burden geographies, with the goal of achieving sustained epidemic control. Over the course of his previous 30-year career in the biopharmaceutical industry, Emilio led teams involved in the research and development of novel anti-infectives and vaccines. From 1983 to 2004, he led research at the Merck Research Laboratories involved in the development of one of the first highly active antiretroviral therapies for HIV and, as senior vice president of vaccine research, the successful development of a number of vaccines including vaccines for human papillomavirus and rotavirus.

He later served as senior vice president of vaccine development at the International AIDS Vaccine Initiative. From 2005 to 2015, he was senior vice president of vaccine R&D at Pfizer Inc., leading the development of Prevnar 13® for prevention of pneumococcal disease.

Emilio was awarded the Distinguished Alumnus Award from the Weill Cornell University Graduate School of Medical Sciences in 2006. He is a former trustee of the National Foundation for Infectious Diseases and a former member of the National Preparedness & Response Science Board, an advisory committee to the U.S. Secretary of Health and Human Services. He is an elected fellow of the American Academy of Microbiology, International Society for Vaccines, and The College of Physicians of Philadelphia. He received his Ph.D. in Microbiology, Genetics, and Biochemistry from the Weill Cornell University Graduate School of Medical Sciences.

Close

Head of Global Regulatory Strategy & Operations

Taryn Rogalski-Salter, Ph.D.

As head of global regulatory strategy and operations at the Bill & Melinda Gates Medical Research Institute, Taryn Rogalski-Salter, Ph.D., and her team develops and implements innovative global regulatory strategies that support accelerated product development, playing a critical role in helping to advance drug and vaccine candidates toward licensure globally.

Throughout her 25-year career in manufacturing, analytical development, global regulatory policy, and regulatory affairs, Taryn has been directly involved in the global licensure of nearly a dozen new vaccines. Prior to joining the Institute, Taryn was vice president and head of global regulatory affairs at Takeda Vaccines, where she was responsible for all regulatory aspects including norovirus, dengue, sIPV, and Zika vaccine candidates. From 2008 to 2012, Taryn served as vice president and global head of vaccine regulatory affairs at Novartis Vaccines & Diagnostics, achieving global licensure of vaccines for influenza and meningitis. As vice president of global regulatory Chemistry, Manufacturing, and Controls (CMC) at Novartis Pharmaceuticals Corporation from 2007 to 2008, she was responsible for all CMC aspects concerning developmental and marketed products. Prior to her work at Novartis, she held various leadership roles in regulatory affairs and global regulatory policy at Merck and GlaxoSmithKline from 1994 to 2007.

Taryn has extensive experience in global regulatory policy and has occupied elected and volunteer positions in pharmaceutical trade organizations including PhRMA, BIO, and IFPMA. Taryn received her Ph.D. from Dartmouth College and conducted her thesis research on applied genetic and metabolic engineering at Dartmouth's Thayer School.

Close

Head of Translational Discovery

Jared Silverman, Ph.D.

As head of translational discovery at the Bill & Melinda Gates Medical Research Institute, Jared A. Silverman, Ph.D., drives products from idea to commercialization in disease areas that disproportionately impact vulnerable populations worldwide.

Jared has more than 20 years of experience in drug discovery spanning multiple therapeutic areas, with a primary focus on antibiotics for the treatment of serious hospital infections. Prior to joining the Institute, Jared was senior vice president of research at Kaleido Biosciences, where he was responsible for building a drug discovery platform to identify novel modulators of the microbiome for the prevention and treatment of disease. From 1997 to 2015, he was a member of the research team at Cubist Pharmaceuticals (including five years as vice president of biology) where he contributed to the discovery of three novel antibiotics that entered clinical development.

Jared has served on the Board of Directors of Auspherix and Procarta Biosciences, and is an editor for Antimicrobial Agents and Chemotherapy. He earned his Ph.D. in Microbiology and Molecular Genetics from Harvard University.

Close

Chief Operating Officer

Debra Weiss, RN, MSN

As chief operating officer at the Bill & Melinda Gates Medical Research Institute, Debra Weiss, RN, MSN, provides strategic and operational support to achieve business objectives in compliance with Institute and industry standards for data integrity, safety, and quality. She has overseen operations since the Institute was founded in January 2018. Prior to her role as COO, Debra served as the Institute’s head of quality assurance & enterprise operations.

Debra’s diverse background ranges from conducting clinical trials in an academic environment to working in large and small pharmaceutical companies, where she traveled globally auditing clinical trial activities and leading global QA organizations. Prior to joining the Institute, Debra served as president of Compliance Driven Performance LLC, where she provided quality assurance and compliance consulting to facilitate companies in building and sustaining their Quality Management System. From 2004 to 2015, she served as group vice president of R&D quality assurance at Shire Pharmaceuticals and was named Shire’s Healthcare Business Women Association Rising Star in 2008. Before Shire, Debra was manager of worldwide clinical quality assurance at Merck & Co., Inc., where she led a team of quality assurance auditors and participated in a pilot program with the FDA on the use of electronic diaries. A registered nurse by training, Debra held various roles at the Hospital of the University of Pennsylvania and Hahnemann University Hospital from 1986 to 1996.

Debra is an adjunct professor at Temple University teaching a graduate course in GCPs. She earned her MSN from the University of Pennsylvania and BSN from Hahnemann University (Drexel).

Close

Chief Medical Officer, Head of Development

Michael Dunne, M.D., FIDSA

As chief medical officer and head of development at the Bill & Melinda Gates Medical Research Institute, Michael W. Dunne, M.D., oversees clinical trials in therapeutic areas aligned with the mission of the Gates Foundation.

Over the course of his career, Michael has played an integral role in global and local anti-infective drug development. Prior to joining the Institute, Michael was the founder and chief scientific officer at Iterum Therapeutics, where he led the development of the antibiotic sulopenem. From 2014 to 2015, he was vice president of research and development at Actavis. Michael earlier served as founder and chief medical officer at Durata Therapeutics beginning in 2009, where he was responsible for the development and successful global registration of dalbavancin. Prior to joining Durata, Michael worked at Pfizer for 17 years, leading the development and registration of several antibacterial, antifungal, antiviral, and HIV therapeutics. Michael was a member of the Scientific Advisory Committee for the Global Alliance for TB Drug Development and a member of the Expert Scientific Advisory Committee for the Medicines for Malaria Venture.

Michael currently serves on the Board of Directors at Iterum Therapeutics and is on the Editorial Review Board of the journal Clinical Infectious Diseases. He is a member of the Scientific Advisory Board for The Singapore-MIT Alliance for Research and Technology and a fellow of the Infectious Diseases Society of America. He earned his M.D. from the State University of New York Health Science Center at Brooklyn and completed his residency in internal medicine and fellowship training in pulmonary medicine and infectious diseases at Yale University.

Close

Head of Program & Portfolio Management

Manfred Lauchart, Ph.D

As head of program & portfolio management at the Bill & Melinda Gates Medical Research Institute, Manfred Lauchart, Ph.D., ensures the delivery of highly-needed medicinal products by driving strategic planning and execution of development programs.

Manfred has extensive product development experience in Fortune 500 Life Science companies, business units, and small biotech start-ups, leading international and cross-functional teams to develop, launch, and sustain life-saving biopharmaceutical and medical device products. Prior to joining the Institute, Manfred served as vice president and head of program management organization at Intarcia Therapeutics, where he drove planning and execution of the pipeline portfolio from 2017 to 2020. Prior to Intarcia, he served as an independent consultant providing and implementing program management solutions for life science companies. As senior director of R&D, head of business operations for global clinical development, and chief of staff at Baxalta, he optimized business processes and secured compliance with existing regulatory requests as well as new R&D standards. From 2003 to 2015, Manfred served as senior director program management office R&D at Baxter Bioscience and Baxter Medical Products divisions, leading international teams in the US, EU, and Asia advancing vaccine, pharmaceutical, and medical device development programs through all stages of product development to licensure and product launch.

Manfred earned his Master of Science in Microbiology and Immunology and his Ph.D. from the University of Vienna, Austria. He later earned a Master of Management degree from Malik Management Centre in St. Gallen, Switzerland.

Close

Lead Counsel

Ken Miller, J.D.

As lead counsel at the Bill & Melinda Gates Medical Research Institute, Ken A. Miller, J.D., delivers efficient and reliable legal guidance, manages legal risk, and supports the development of solutions that accelerate impact.

Ken is a business, technology, and global health attorney with more than 20 years of experience working with highly innovative companies and nonprofits, focusing on the life sciences, software, and semiconductor industries, to help them achieve their business and charitable objectives. Prior to joining the Gates MRI in 2021, Ken supported the Global Health Division of the Bill & Melinda Gates Foundation for five years as associate general counsel, where he helped to structure and negotiate some of the Foundation’s most substantial investments and collaborations in TB, HIV, and vaccine development. From 2005 to 2015 he was a partner of the Technology Transactions and Privacy Group at Perkins Coie LLP. In this role, Ken advised technology companies and nonprofits in complex, high-value IP and commercial transactions covering the entire product life cycle, from discovery through manufacturing and commercialization for small molecules, biologics, and devices.

Ken is a member of the Licensing Executives Society and a member of the Board of Trustees and Executive Committee at Epiphany School. He earned his J.D. from Seattle University School of Law.

Close

Head of Corporate Strategy

Claire Wagner, M.D., MBA

As head of corporate strategy at the Bill & Melinda Gates Medical Research Institute, Claire M. Wagner, M.D., M.B.A., drives forward the Institute’s mission and vision, advising the CEO on enterprise-level strategy across a range of vantage points. Prior to her role as head of corporate strategy, Claire served as chief of staff.

Claire has led multi-country studies and consulted for industry and non-profit entities focused on enhancing global access to oncology products and services in low- and middle-income countries. Prior to joining the Institute, Claire worked in Mali and Tanzania between 2007 and 2009 and later served in Rwanda from 2010 to 2013 on a research team advancing large public sector health initiatives.

After returning to the United States, Claire coordinated a global effort led by the Dana-Farber Cancer Institute and the Union for International Cancer Control, resulting in the 16-drug expansion of the World Health Organization's Model List of Essential Medicines for cancer. As a research fellow of the Harvard-Dubai Center for Global Health Delivery in 2018-19, Claire was principal investigator on a study evaluating access to cancer diagnostics in the East African Community.

Claire is the recipient of The Commonwealth Institute’s 2021 Extraordinary Women Advancing Healthcare Award. She is an associate scientist in medicine in the Division of Global Health Equity at the Brigham and Women’s Hospital and is a co-author of more than 40 scientific publications in peer-reviewed journals, including Nature, The Lancet, and The New England Journal of Medicine. Claire earned her M.D. from Harvard Medical School and her M.B.A. from Harvard Business School, where she was the Commencement Class Day Speaker.

Close

Approach

How We Work

Scientific discovery followed by product development and delivery is one formula for saving lives. It has turned HIV from a death sentence into a disease people can live with. It turned smallpox into a disease no one has to live with.

Right now, scientists know more about human biology than they ever have before. They have the computing power to simulate complex biological processes, and to do it incredibly quickly. The universe of the possible keeps expanding.

However, the necessary funding, tools and commitment have only rarely been brought together to serve the needs of the world’s poorest people. It’s time to use the latest innovations to improve all lives. We will combine advances in biomarker profiling of the immune system and infectious organisms and bioassays, quantitative sciences and statistical computing, and expertise in chemistry and manufacturing to move potential solutions from the laboratory into human trials.

We are part of a large community with shared goals, and we know we will reach those goals faster together. We rely on academic researchers, biotechnology and pharmaceutical companies, and global health organizations as partners in our work. We will share what we learn with our partners to accelerate the cycle of innovation.

Research

Priorities

  • Malaria
  • Tuberculosis
  • Diarrheal Disease
  • Maternal, Newborn, and Child Health
Eradicate malaria

Malaria may have killed half the people who have ever lived1. Every year, it kills almost 500,000 people and makes more than 200 million sick. As we drive toward zero deaths and zero cases, we will need a next-generation vaccine and drugs that combat resistance. See diagram attributions.

Accelerate the end of tuberculosis

Tuberculosis is currently the leading cause of death from infectious disease2. The treatment regimen we use today is long and complicated, and hundreds of thousands of cases are resistant to the standard drugs. To control the disease, we need a shorter, simpler course of treatment that works for both drug-sensitive and drug-resistant TB. Eventually, we need an effective vaccine. See diagram attributions.

End diarrheal deaths

Diarrhea is the second leading cause of death among children3. Virtually all those deaths occur in low-income countries. A recently developed vaccine for rotavirus, once the leading cause of diarrhea, has started to reduce mortality. Now, we need to tackle diarrhea's many other causes. See diagram attributions.

Improve outcomes in maternal and newborn child health

Globally, more than 2 million babies are still-born every year, and a similar number of babies die within the first month of life. Preterm birth is a major contributor to neonatal deaths, and many preterm babies die because their lungs are not ready for life outside the womb. Provision of antenatal corticosteroids and supplementation of lung surfactant have the potential to save many babies born prematurely. See diagram attributions.

Pipeline

 Preclinical


MRI TBD05 (SPR720)
MRI TBD01 (Sutezolid)
MRI EDV01 (Shigella Synthetic Conjugate Vaccine)
MRI MND01 (Dry Powder Lung Surfactant)
MRI RSM01 (RSV mAb)

 Phase 1

 Phase 2/3


MRI TBV02
(M72/ASO1)
MRI TBV01-201
(BCG REVAX)
TBD06
(TB Drug Regimen)
MRI TBD03-201
(TBA 7371)
TUBERCULOSIS
MALARIA
DIARRHEAL DISEASES
MATERNAL, NEWBORN, AND CHILD HEALTH
RESPIRATORY SYNCYTIALVIRUS
TUBERCULOSIS
MALARIA
DIARRHEAL DISEASES
MATERNAL, NEWBORN, AND CHILD HEALTH
RESPIRATORY SYNCYTIALVIRUS

Malaria, diarrheal diseases, and tuberculosis kill five people every minute.4

We believe we can help end this crisis.

Our bottom line is lives saved.

Gates MRI

FAQ

What is the relationship between the Gates MRI and the Bill & Melinda Gates Foundation?

  • The Gates MRI is subsidiary of the Bill & Melinda Gates Foundation funded by a grant from the foundation.
  • The Gates MRI is aligned with the vision of the Bill & Melinda Gates Foundation and guided by the belief that all lives have equal value.
Where is the Gates MRI located?

The Gates MRI is headquartered in Cambridge, Massachusetts.

Where can I find more information or inquire about job opportunities?

Further information about job opportunities and other updates about the Gates MRI can be found on the organization's careers page. If you would like to submit your resume to our human resources department, please send to [email protected]

How large is the Gates MRI? How many employees does Gates MRI have?

The Gates MRI plans on operating as a fully integrated, non-profit biotech organization staffed appropriately to advance a pipeline of programs in the prioritized disease areas from pre-clinical testing through human proof of concept studies. We expect we will scale up to 80 to 120 full-time employees over the next several years.

Does the Gates MRI provide research grants?

No, the Gates MRI is a non-profit biotech organization focused on accelerating product development for diseases that affect the world’s poorest populations. We do not anticipate making grants at this time.

Does the Gates MRI accept donations?

The Gates MRI does not solicit donations from the public. We are proud of our mission to develop products to fight malaria, tuberculosis, and diarrheal diseases, and encourage people who share our passion for saving lives to donate to causes aligned with their values.

What is the distinction between the Gates MRI and the Coalition for Epidemic Preparedness Innovations (CEPI)?

CEPI is focused on accelerating the development of vaccines for emerging infectious diseases. The Gates MRI will focus on developing interventions to fight persistent epidemics, such as malaria, tuberculosis, and enteric and diarrheal diseases.

Do you have a pool of product candidates to research? What is the Gates MRI pipeline of programs?

The team at Gates MRI is currently evaluating a number of products under development with foundation partners. Once this analysis is completed, we will share the pipeline.

How will the Gates MRI share its findings?

The Gates MRI will adhere to the foundation’s global access and open access policies.

  • Global Access, a core value of the foundation, rests on two principles: (a) prompt and broad dissemination of knowledge and information; and (b) access to products at an affordable price to people most in need. Gates MRI will manage our research activities in accordance with Global Access to ensure impact for its intended beneficiaries.
  • Open Access enables unrestricted access and reuse of all peer-reviewed published research that has been funded by the foundation, including underlying data sets, and removes the publisher pay wall for access to this information.
What research and development partnerships will the Gates MRI pursue?

Focused on serving as a convener and connector in the research and development community, the Gates MRI will collaborate with foundation product development partners, academia, pharmaceutical and biotech companies, LMIC manufacturers and non-profit organizations on upstream and downstream activities. We will establish partnerships that leverage assets, capabilities and expertise in order to accelerate product development for our disease areas of interest. The Gates MRI actively and continuously engages directly in the conduct of medical research in conjunction with one or more hospitals for the purpose of addressing major causes of illness and death in LMIC.

Will the Gates MRI only take product development to phase 2? Assuming a viable candidate is developed, how will the Gates MRI identify partners to bring products through to commercialization?

The Gates MRI will focus on translational product development, (defined as preclinical candidate selection to human/clinical proof of concept in the target population). Once a candidate has achieved human proof of concept, the plan is to partner the program with an organization that has late-stage development and commercial expertise. Late-stage development partners may include non-profit product development partners, LMIC manufacturers, and pharmaceutical companies.

How will the Gates MRI ensure that products developed by the organization will be made available to the world's poorest populations at an acceptable volume and affordable price?

The Gates MRI will adhere to the foundation's Global Access policy. Organizations that partner with the foundation agree to Global Access, which requires that the knowledge and information gained from a funded project will be promptly and broadly disseminated, and that funded developments will be made available and accessible at an affordable price to people in need within LMIC.

CAREERS

Join Our Team

The Gates MRI is a diverse group of passionate change-makers, creative fixers and relentless advocates. We are committed to saving lives by improving the pace and predictability of translational medicine in global health. We will relentlessly seek out innovative strategies to develop the best drugs, biologics, and vaccines to fight some of the toughest, most complex disease problems in the world. Our focus is translating findings from basic science into potential solutions that will fill the product pipeline for malaria, tuberculosis, and enteric and diarrheal diseases to start.

Our culture thrives on our five mantras:

  • Urgency: Strive every day to do better than your last best accomplishment.
  • Collaboration: Solving the world’s most complex disease burdens is a team effort.
  • Innovation: Uncover new methods, approaches and solutions to achieve unprecedented results.
  • Rigor: Follow the science with passion and perseverance.
  • Courage: Pursue progress boldly to deliver on our bottom line: lives saved.

We are bringing together top talent from diverse scientific backgrounds to work across a range of disease areas and modalities, building upon the best work being done in scientific discovery, constantly pushing the envelope, and embracing new methodologies.

The Gates MRI aims to use quantitative sciences; to develop strong biomarker strategies upfront, and understand production issues early on to drive greater rigor in global health clinical research, enabling potentially faster development of products for diseases of the poorest. We will seek to publish our learnings, so that they will be available to all research and development communities through our commitment to open access.

If you share our belief that all lives have equal value, and that science and technology can change lives for the better, we would love to connect with you. Please review our Current Opportunities through the link below and apply directly for consideration: LinkedIn or submit your resume to human resources at [email protected].

Get Involved

Connect

REFERENCES
1. Whitfield J. Portrait of a serial killer. Nature. 2002. doi:10.1038/news021001-6.
2. Global Health Observatory (GHO) data: Tuberculosis (TB). World Health Organization Web site. http://www.who.int/gho/tb/en/. Accessed May, 2018.
3. Global Diarrhea Burden. Centers for Disease Control and Prevention Web site. https://www.cdc.gov/healthywater/global/diarrhea-burden.html. Updated December 17, 2015. Accessed May, 2018.
4. WHO Diarrhoeal disease fact sheet, updated May 2017; WHO Malaria Policy and Advisory Committee Meeting Report 2018; WHO Global Tuberculosis Report 2017.